Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.

The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...

Stocks are set to close out April with major gains even as a war in the Middle East is ongoing, and fears around AI ...

Recognizing the signs of mild cognitive impairment meant Di could start treatment earlier to help slow her Alzheimer's ...

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

No new signals for lecanemab emerged in ALZ-NET ...

Investigational deramiocel is back under FDA review again ...

Researchers at Mass General Brigham, the Broad Trauma Initiative , and Harvard T.H. Chan School of Public Health have identified scalable ...

Karin-Mari Dötze lands a Nedbank sponsorship after a Two Oceans Marathon bib-switch scandal briefly cost her a Top 10 finish ...

Evercore ISI upgrades Intel to outperform from in line Evercore upgraded the stock following earnings on Thursday. "Improved ...

The S&P 500 and Nasdaq raced ahead to more record highs on Friday amid rising optimism about US-Iran peace talks this weekend ...

Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go ...